$SNSE News

Cantor Fitzgerald Initiates Coverage On Sensei Biotherapeutics with Overweight Rating

LUCID CAPITAL MARKETS Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $50

Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $55

Sensei Biotherapeutics Q1 EPS $(131.45) Misses $(0.62) Estimate

Sensei Biotherapeutics Says First Patient Dosed In Study FTH-PIK-101, Phase 1b/2 Trial Of PIKTOR In Patients With HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics Files Prospectus To Register 24.9M Shares For Resale By Selling Shareholders

Sensei Biotherapeutics Q4 EPS $(3.74) Beats $(4.11) Estimate

Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule

Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (SNSE) Faeth Therapeutics, Inc. - M&A Call - Slideshow

Sensei Biotherapeutics Stock Soars 230% After Faeth Deal

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Sensei Biotherapeutics shares are trading higher. The company announced a $200 million concurrent private placement.

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Sensei Biotherapeutics Announces $200M Concurrent Private Placement

Sensei Biotherapeutics Acquires Faeth Therapeutics In Stock-To-Stock Transaction

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

Egle Therapeutics Appoints John Celebi as Chief Executive Officer

What Sparked Sensei Biotherapeutics (SNSE) Stock's Nearly 63% After‑Hours Jump?